VIDEO: Immunotherapy alone shows benefit in older patients with NSCLC

ByRavi Salgia, MD, PhD

ByMarley V. Ghizzone

Fact checked byMindy Valcarcel, MS

Ravi Salgia, MD, PhD, spoke with Healio about findings presented at ASCO Annual Meeting from a FDA pooled analysis of first-line treatment options for patients with PD-L1 advanced non-small cell lung cancer.

“It was important to realize that in the elderly population — that is in [those] 75 years or older — the immune therapy by itself gave good results,” Salgia, medical oncologist, professor and Arthur & Rosalie Kaplan Chair of the medical oncology and therapeutics research department at City of Hope, said.

Reference:

Akinboro O, et al. Outcomes of anti–PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non–small cell lung cancer (NSCLC) with PD-L1 score 50%: FDA pooled analysis. Presented at: ASCO Annual meeting; June 3-7, 2022; Chicago.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: Salgia reports no relevant financial disclosures.

Take Homes in Lung Cancer

Read more

VIDEO: Immunotherapy alone shows benefit in older patients with NSCLC

Reference:

Related Content